EVENT DETAILS
Thursday, May 3, 2018
Albany Marriott
189 Wolf Road
Albany, NY 12205
Time
8:00 AM - 5:00 PM
Total Credits
7 Contact Hour(s)
Target Audience
Pharmacist , Pharmacy Technician
Cost
$129.00
Registration closes on 5/3/2018 at 6:00 AM
 

Registration will be held from 8:00 am - 8:30 am. Continental breakfast will be served during this time.

A plated lunch will be served from 12:00 pm - 1:00 pm.

Refreshments will be served during the afternoon programs.

 

AGENDA

Scheduled CE Activities Thursday, May 3, 2018
  
Major advances have been made in managing HCV infection in recent years with the advent of Direct Acting Antiviral (DAA) therapy. This presentation will review recent changes to AASLD HCV Management Guidelines and highlight the role of new pangenotypic regimens for HCV. In addition, the role of the pharmacist will be discussed as it relates to drug selection, prevention of drug drug interactions and cost containment.
 
 
Pharmacist Learning Objectives
  • List and review recent changes to AASLD HCV Guidelines
  • Describe the role pangenotypicia regimens in managing HCV
  • Compare and contrast the role of HCV management in HCV monoinfected and HIV/HCV co-infected patients
  • List the common drug interactions likely to occur with HCV medication
  • Provide reputable resources for managing HIV and HCV co-infection
Pharmacy Technician Learning Objectives
  • Describe the role of ancillary staff and technicians in securing HCV medications
  • Provide three interventions that technicians can provide to assist patients in maintaining adherence to HCV regimens
 
Faculty
John FaragonPharmD, BCPS, AAHIVP
Regional Pharmacy Director, North East Caribbean AIDS Education and Training Center
 
ACPE UAN
0280-9999-18-017-L01-P (Knowledge-Based)
0280-9999-18-017-L01-T (Knowledge-Based)
 
Credits
1.5
 
Handouts
 
Supported By
AIDS Education & Training Center
 
Pharmacy has been thrust into the national spotlight as solutions are sought to manage the inappropriate distribution of prescription medications. This session seeks to explore various tools available to the pharmacy staff to combat illicit distribution, while maintaining appropriate and legitimate patient access to prescribed medications. The effectiveness and limitations of state Prescription Drug Monitoring Programs (PDMPs) are discussed in the context of “red flag” behaviors that may suggest inappropriate distribution. The session further seeks to identify current trends in the use and misuse of controlled substances from multiple professional, sociological, and regulatory perspectives.
 
 
Pharmacist Learning Objectives
  • Identify the role, proper use, and limitations of state Prescription Drug Monitoring Programs (PDMPs) in determining appropriate access to controlled substance medications
  • Identify common 'red flags' that should initiate further investigation when considering the validity of a controlled substance prescription, including the assessment of appropriate therapeutic value
  • Describe current trends related to the abuse of prescription drugs
Pharmacy Technician Learning Objectives
  • Identify the role, proper use, and limitations of state Prescription Drug Monitoring Programs (PDMPs) in determining appropriate access to controlled substance medications
  • Identify common 'red flags' that should initiate further investigation when considering the validity of a controlled substance prescription, including the assessment of appropriate therapeutic value
  • Describe current trends related to the abuse of prescription drugs
 
Faculty
Kevin HopeRPh
Clinical Education Specialist and Continuing Education Administrator, PharmCon, Inc.; Advisory Board Member, Paradigm Education Solutions; Nuclear Pharmacist, Triad Isotopes
 
ACPE UAN
0280-0000-18-012-L04-P (Knowledge-Based)
0280-0000-18-012-L04-T (Knowledge-Based)
 
Credits
1.5
 
Handouts
 
Supported By
American Health Resources, LLC.
 
 
 
Pharmacist Learning Objectives
  • Describe the impact that the pharmacist has on maintaining safety in patients on DOAC therapy
  • Summarize current indications for DOAC therapy
  • Determine an appropriate DOAC agent and dose for a patient based on their weight and renal function
  • Recommend appropriate management of potential drug interactions with the DOACs
  • Review appropriate periprocedural resources to manage a patient's DOAC before and after an invasive procedure
Pharmacy Technician Learning Objectives
  • List DOAC brand names, generic names and indications
  • Recognize appropriate dosing of DOAC therapy
  • Summarize significant drug interactions with DOAC therapy that would lead to follow up with the ordering provider
 
Faculty
Katherine CabralPharmD
Associate Professor, Albany College of Pharmacy and Health Sciences
 
ACPE UAN
0280-0000-18-016-L01-P (Knowledge-Based)
0280-0000-18-016-L01-T (Knowledge-Based)
 
Credits
2
 
Handouts
 
Supported By
American Health Resources, LLC.
 
This presentation will provide pharmacists and pharmacy technicians with knowledge to identify common medication errors and safety concerns associated with anti-inflammatory and disease modifying therapies used to treat inflammatory disease including rheumatoid arthritis, osteoarthritis, psoriatic arthritis, crohn’s disease and gout. Medications that will be discussed include NSAIDs, corticosteroids, anti-gout medications, immunosuppressants, conventional disease modifying antirheumatic drugs (DMARDs) and biologic DMARDs.
 
 
Pharmacist Learning Objectives
  • Identify patient safety concerns and potential medication errors associated with therapies used to treat autoimmune and inflammatory diseases
  • Evaluate the precautions, contraindications and warnings involving the use of biologic DMARDs in high risk patients (i.e., hepatitis, heart failure, and malignancy)
  • Demonstrate the ability to provide effective safety education and guidance to patients, caregivers, and other health care providers on the use of anti-inflammatory and disease modifying therapies.
  • Devise strategies to minimize risks associated with the use of disease modifying agents through pharmacist-provided monitoring programs
Pharmacy Technician Learning Objectives
  • Recognize common anti-inflammatory or disease modifying therapies associated with medication errors
  • Recall patient safety concerns associated with therapies used to treat autoimmune and inflammatory diseases
 
Faculty
Jessica FarrellClinical Pharmacist/Associate Professor
Albany College of Pharmacy & Health Sciences
 
ACPE UAN
0280-0000-18-014-L05-P (Knowledge-Based)
0280-0000-18-014-L05-T (Knowledge-Based)
 
Credits
1
 
Handouts
 
Supported By
American Health Resources, LLC.
 
On July 7th, 2014, Governor Andrew M. Cuomo signed into law the Compassionate Care Act to establish a comprehensive Medical Marijuana Program in New York State. New York’s program allows patients who suffer from specific serious conditions to be certified by a practitioner to receive medical marijuana products for medical use. Ten organizations are currently registered with the program and are responsible for manufacturing and dispensing medical marijuana in New York. Each registered organization is permitted by statute to have up to four dispensing facilities. As of March 2018, there were over 48,000 certified patients and over 1,500 practitioners participating with the program.

 

 
 
Pharmacist Learning Objectives
  • Explain the Compassionate Care Act which comprehensively regulates the manufacture, sale and use of medical marijuana in New York State.
  • Describe the role of the registered organizations in the New York State program.
  • Summarize recent medical marijuana program updates.
Pharmacy Technician Learning Objectives
  • Explain the Compassionate Care Act which comprehensively regulates the manufacture, sale and use of medical marijuana in New York State.
  • Describe the role of the registered organizations in the New York State program.
  • Summarize recent medical marijuana program updates.
 
Faculty
Judith BarrettRPh
Pharmacist, New York State Medical Marijuana Program
Nicole QuackenbushPharmD
Director, New York State Medical Marijuana Program
 
ACPE UAN
0280-0000-18-019-L03-P (Knowledge-Based)
0280-0000-18-019-L03-T (Knowledge-Based)
 
Credits
1
 
Handouts
 
Supported By
American Health Resources, LLC.
 
 
 
 
Requirements for CE Credit
  • Participant Requirement and Statement of Credit: To receive credit, participants must fully attend each session (no partial credit will be awarded), pass in a completed attendance verification form, and using the access code provided, complete the online evaluation for each session attended. Attendance will be verified. All participants will have the opportunity to evaluate the educational sessions and presenters as well as the ability to identify their
  • Pharmacists and Pharmacy Technicians: CE credit will be automatically uploaded to CPE Monitor upon completion of the evaluation and posted to the participant’s NABP account within 72 hours where an official certificate of credit can be printed. Evaluations must be completed within 60 days of program date to receive credit.
  • Statement of Disclosure: Disclosure will be made on the day of the program regarding any interest or affiliation a speaker may have with a supporting organization.
  • Refund Policy: A full refund will be provided only if a written request is received by American Health Resources, LLC at least 48 hours prior to the program or if the program is cancelled. American Health Resources, LLC reserves the right to change the presenters, topics or seminar schedules.
 
Only Certificates of Credit issued from CPE Monitor are valid in the US.
CPE Monitor will not accept credits after 60 days from the session date.
 
Supported By:
American Health Resources, LLC.
 
Registration closes on 5/3/2018 at 6:00 AM
 

CONTINUING EDUCATION

843 488 5550 Office

843 488 5554 Fax

info@ahrevents.com Email

www.ahrevents.com Web

341 Wellness Drive, Myrtle Beach, SC 29579 Address

©2015 PharmCon, lnc. All Rights Reserved | Terms & Conditions | Privacy PolicyAmerican Health Resources, LLC a subsidiary of PharmCon, Inc.
Developed By: ITB, Inc.